drugset / Trial / NCT02207556
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
Phase 2
Completed
32 enrolled
Medical College of Wisconsin
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis. The investigators want to find out whether doxycycline improves the response to standard anti-amyloid therapy and whether it causes any problems (side effects).
Timeline
- Start
- 2014-10-01
- Primary completion
- 2017-07-31
- Completion
- 2020-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxycycline | Small molecule | 100 mg | Oral |